Core Viewpoint - Walgreens Boots Alliance is set to be acquired by Sycamore Partners for a total of $23.7 billion, including debt, with the deal expected to close by the end of the year [1] Group 1: Acquisition Details - The equity value of the acquisition is approximately $10 billion, with Sycamore paying $11.45 per share for Walgreens [1] - Shareholders may receive an additional $3 per share if Sycamore sells Walgreens' primary care operations, potentially raising the total value to $14.45 per share, representing a 26% gain [3] Group 2: Market Reaction - Walgreens stock closed at $11.10, which is about 3% below the purchase price of $11.45, indicating that the market has already priced in the acquisition [2] - The small difference between the current stock price and the acquisition price suggests a high level of confidence in the deal's completion [2] Group 3: Risks and Considerations - The potential for profit exists, but the acquisition price creates a ceiling on stock value, limiting upside potential [4] - Historical examples, such as Microsoft's acquisition of Activision Blizzard, illustrate that market hesitance can lead to stock price fluctuations until confidence in the deal solidifies [5][6] - Walgreens shares have declined over 75% in the past five years, and the company is undergoing a challenging turnaround, which may complicate its future performance [7] Group 4: Investment Outlook - While there may be a small profit opportunity, the overall risk associated with investing in Walgreens is significant, especially compared to other stocks with better growth potential [9][10]

Core Viewpoint - Walgreens Boots Alliance, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its compliance with federal laws related to prescription medication [3][4]. Summary by Relevant Sections Allegations - The lawsuit claims that during the class period from April 2, 2020, to January 16, 2025, Walgreens engaged in widespread violations of federal law concerning the dispensation of prescription medication and reimbursement [3]. - It is alleged that Walgreens' revenues from prescription medication sales were unsustainable as they were derived from unlawful conduct, which could lead to increased regulatory scrutiny, civil liability, and reputational harm [3]. Class Action Details - Shareholders who purchased WBA shares during the specified class period are encouraged to register for the class action, with a deadline set for March 31, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - A class action lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged violations of federal securities laws during the Class Period from April 2, 2020, to January 16, 2025, seeking damages for affected investors [1] Company Overview - Walgreens operates as a healthcare, pharmacy, and retail company in the U.S., U.K., Germany, and internationally, with three reportable segments: U.S. Retail Pharmacy, International, and U.S. Healthcare [4] - The U.S. Retail Pharmacy segment includes retail drugstores, health and wellness services, and specialty and home delivery pharmacy services, with a significant portion of sales derived from prescription drugs reimbursed by third-party payors [4] Legal and Regulatory Context - Walgreens must comply with various federal statutes, including the Controlled Substances Act (CSA) and the False Claims Act (FCA), which govern the dispensation of controlled substances and reimbursement claims [5][6] - The opioid crisis in the U.S. has led to increased scrutiny of Walgreens' practices, with the company previously settling multiple legal claims related to its role in the opioid epidemic [6][7] Allegations and Lawsuit Details - The complaint alleges that Walgreens made materially false and misleading statements regarding its business operations and compliance with federal laws, leading to unsustainable revenues from unlawful conduct [9] - The Department of Justice (DOJ) filed a civil complaint against Walgreens, alleging the company dispensed millions of unlawful prescriptions and sought reimbursement from federal health care programs [10] - Following the DOJ's announcement, Walgreens' stock price fell by 12.06%, indicating a significant market reaction to the allegations [10]

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between April 2, 2020 and January 16, 2025, both dates inclusive (the “Class Period”), of the important March 31, 2025 lead plaintiff deadline. SO WHAT: If you purchased Walgreens common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that Walgreens failed to disclose significant issues regarding regulatory compliance and unlawful conduct related to prescription medication, which led to misleading public statements and potential damages for investors [4]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in recovering substantial amounts for investors [5]. - Investors are informed that no class has been certified yet, meaning they are not represented unless they retain counsel, and they can choose to remain absent from the class [7].

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form-2/? id=137118&from ...

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for Walgreens Boots Alliance (WBA) despite an increase in revenues, with actual results being crucial for stock price movement [1][3]. Earnings Expectations - The expected quarterly earnings per share (EPS) for Walgreens is $0.53, reflecting a year-over-year decrease of 55.8% [3]. - Revenues are projected to reach $37.92 billion, which is a 2.4% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.82% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - A positive Earnings ESP of +9.39% suggests that analysts are optimistic about Walgreens' earnings prospects [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Walgreens currently holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Walgreens exceeded the expected EPS of $0.37 by delivering $0.51, resulting in a surprise of +37.84% [12]. - Over the past four quarters, Walgreens has beaten consensus EPS estimates three times [13]. Conclusion - While Walgreens is positioned as a compelling earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [16].

Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Walgreens made false statements regarding its commitment to regulatory compliance while continuing to violate federal laws related to prescription medication [2]. - It is alleged that the company's unlawful conduct posed a risk of increased regulatory scrutiny, civil liability, and reputational damage [2]. - The revenues from prescription medication sales were deemed unsustainable due to their reliance on unlawful practices, rendering Walgreens' public statements materially false and misleading [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/walgreens-boots-alliance-inc-loss-submission-form-2/?id=136057&from= ...

Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Walgreens made false statements and concealed ongoing violations of federal law regarding prescription medication dispensation and reimbursement [2]. - It is alleged that Walgreens' conduct would lead to increased regulatory scrutiny, civil liability, and reputational damage [2]. - The complaint asserts that Walgreens' revenues from prescription medication sales were unsustainable due to unlawful practices, rendering public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].